

Lifeline Drugs & Pharma Limited

Regd Office : 17, 3rd Floor, Zaveri Bhavan, 85/87, Old Hanuman Lane, Kalbadevi Road, Mumbai-400 002

Rs. in Lacs

Statement of Audited Results for the Quarter & 12 months ended 31st March 2013

Sr. No.	Particulars	3 Months ended	Preceding 3	Corresponding 3	Year to date	Year to date
		31.03.2013	Months ended	Months ended	figures as on	figures as on
			31.12.2012	31.03.2012	31.03.2013	31.03.2012
		Un-Audited			Audited	
1	Income from Operations					
	a) Net Sales/Income from Operations	-	-	-	-	-
	b) Other Operating Income	-	-	-	-	-
	Total Income from Operations (Net)	-	-	-	-	-
2	Expenses					
	(a) Cost of Material Consumed	-	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(d) Employees Benefit Expenses	1.03	1.12	(0.42)	3.75	2.30
	(e) Depreciation & Amortization Expenses	-	-	-	-	-
	(f) Exchange & Depository Expenses	0.15	0.87	(2.85)	3.00	-
	(g) Other Expenditure	(3.93)	1.56	0.86	1.51	6.30
	Total Expenses	(2.75)	3.55	(2.41)	8.26	8.60
3	Profit/(Loss) from Operations before other Income, finance cost and exceptional Expenses (1-2)	2.75	(3.55)	2.41	(8.26)	(8.60)
4	Other Income/(Loss)	3.46	8.68	3.46	28.64	13.47
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	6.21	5.13	5.87	20.38	4.87
6	Finance Costs	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3-4)	6.21	5.13	5.87	20.38	4.87
8	Exceptional Items	-	-	-	-	-
9	Profit(+)/Loss(-) from ordinary activities before Tax (7-8)	6.21	5.13	5.87	20.38	4.87
10	Tax Expense	-	-	-	6.30	1.65
11	Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)	6.21	5.13	5.87	14.08	3.22
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11-12)	6.21	5.13	5.87	14.08	3.22
14	Share of Profit/(Loss) of Associates*	-	-	-	-	-
15	Minority Interest*	-	-	-	-	-
16	Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)	6.21	5.13	5.87	14.08	3.22
17	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	307.40	233.60	24.00	307.40	24.00
18	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	968.27	113.19
19	Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not annualized)					
(i)	a) Basic	0.20	0.22	2.45	0.46	1.34
	b) Diluted	0.20	0.22	2.45	0.46	1.34
19	Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not annualized)					
(ii)	a) Basic	0.20	0.22	2.45	0.46	1.34
	b) Diluted	0.20	0.22	2.45	0.46	1.34
A	PARTICULARS OF SHAREHOLDING					
	Public Shareholding					
	- Number of Shares	3,071,500	2,333,500	138,790	3,071,500	138,790
	- Percentage of Share Holding	99.92	99.89	57.83	99.92	57.83
18	Promoter and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-
	b) None-Encumbered					
	- Number of Shares	2,500	2,500	101,210	2,500	101,210
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	0.08	0.11	42.17	0.08	42.17
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the Quarter	-	Disposed during the Quarter		-	-
	Received during the Quarter	-	Remaining Unresolved at the end of Quarter		-	-

Notes :

- Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
- Above results were reviewed by Audit Committee taken on record in Board Meeting held on May 30, 2013.
- During the Quarter, the Company has allotted 7,38,000 Equity Shares at a price of Rs. 60/- per Share on Preferential basis to Non-Promoter Group.
- The figures of last Quarter are the balancing figures between Audited figures in respect of full financial year and the published year to date figures upto the 3rd Quarter of the Current Financial Year.
- The Statutory Auditors of the Company have carried out Audit for the above Financial Results.

Place : Mumbai
Date : 30th May 2013

For Lifeline Drugs & Pharma Limited
S/d-
Alok Behera
Managing Director

Lifeline Drugs & Pharma Limited
Statement of Assets & Liabilities

Rs. in Lacs

Particulars		For the Year Ended	
		31-Mar-2013	31-Mar-2012
		Un-Audited	Audited
A	EQUITY & LIABILITIES		
1	Shareholders' Fund		
	(a) Share Capital	307.40	24.00
	(b) Reserves and Surplus	968.27	113.19
	(c) Money Received against Share Warrants	-	-
	Sub-Total - Share Holders Fund	1,275.67	137.19
2	Share Capital Money (Pending Allotment)	-	-
3	Minority Interest*	-	-
4	Non Current Liabilities		
	(a) Long Term Borrowings	-	-
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-Total - Long Term Liabilities	-	-
5	Current Liabilities		
	(a) Short Term Borrowings	-	-
	(b) Trade Payables	-	0.30
	(c) Other Current Liabilities	-	6.83
	(d) Short Term Provisions	21.72	14.61
	Sub-Total - Current Liabilities	21.72	21.74
	TOTAL EQUITY & LIABILITIES	1,297.39	158.93
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets	-	-
	(b) Goodwill on Consolidation*	-	-
	(c) Non-Current Investments	-	-
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long Term Loans & Advances	-	-
	(f) Other Non-Current Assets	-	-
	Sub-Total - Non Current Assets	-	-
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	840.33	0.44
	(c) Trade Receivables	169.57	141.38
	(d) Cash & Cash Equivalents	10.84	3.65
	(e) Short Term Loans & Advances	276.65	-
	(f) Other Current Assets	-	13.46
	Sub-Total - Current Assets	1,297.39	158.93
	TOTAL - ASSETS	1,297.39	158.93